{"id":15881,"date":"2023-07-25T16:15:00","date_gmt":"2023-07-25T08:15:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15881"},"modified":"2024-11-30T16:39:08","modified_gmt":"2024-11-30T08:39:08","slug":"roche-and-alnylam-partner-on-rnai-therapeutic-zilebesiran-for-hypertension-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15881","title":{"rendered":"Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment"},"content":{"rendered":"\n<p>Swiss pharmaceutical giant Roche (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROG:SWX\">SWX: ROG<\/a>) has signed a deal with US-based RNAi specialist Alnylam (<a href=\"https:\/\/www.google.com\/finance\/quote\/ALNY:NASDAQ\">NASDAQ: ALNY<\/a>), securing rights to co-develop and co-commercialize Alnylam\u2019s zilebesiran, a Phase II stage RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension.<\/p>\n\n\n\n<p><strong>Financial Terms and Collaboration Details<\/strong><br>Under the agreement, Roche will pay Alnylam an upfront fee of USD 310 million, with development and commercial milestones that could bring the total potential deal value to USD 2.8 billion. The collaboration will see Roche and Alnylam co-commercialize the therapy in the United States, sharing profits equally, while Roche will hold full commercial rights in other territories, in return for a low-double-digit royalty on future sales.<\/p>\n\n\n\n<p><strong>Development and Potential Impact of Zilebesiran<\/strong><br>Alnylam will lead the development of zilebesiran in its first indication as a treatment for general hypertension, either as a monotherapy or in combination with other anti-hypertensives. The drug candidate offers a once-every-six-months dosing schedule and is considered a potentially transformational \u201cbest-in-disease\u201d treatment, particularly for patients with hypertension at high cardiovascular risk. Zilebesiran is currently the subject of two Phase II trials in patients with mild to moderate hypertension.<\/p>\n\n\n\n<p><strong>Clinical Trials and Recruitment Details<\/strong><br>KARDIA-1, the first trial, is assessing zilebesiran as a monotherapy, with enrollment of 400 patients already completed. The second trial, KARDIA-2, will assess the molecule in combination with one of three standard-of-care antihypertensive medications \u2013 Pfizer\u2019s Norvasc (amlodipine), and Daiichi Sankyo\u2019s Benicar (olmesartan) or Lozol (indapamide). This trial aims to recruit 600 patients, further expanding the clinical evaluation of zilebesiran&#8217;s potential in hypertension treatment.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2088,108,2087,64,163,939],"class_list":["post-15881","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-alnylam-pharmaceutical","tag-high-blood-pressure","tag-nasdaq-alny","tag-rnai-aso","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam (NASDAQ: ALNY), securing rights to co-develop and co-commercialize Alnylam\u2019s zilebesiran, a Phase II stage RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15881\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15881\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-25T08:15:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-30T08:39:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15881#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15881\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment\",\"datePublished\":\"2023-07-25T08:15:00+00:00\",\"dateModified\":\"2024-11-30T08:39:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15881\"},\"wordCount\":269,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Alnylam Pharmaceutical\",\"High blood pressure\",\"NASDAQ: ALNY\",\"RNAi \\\/ ASO\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15881#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15881\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15881\",\"name\":\"Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-25T08:15:00+00:00\",\"dateModified\":\"2024-11-30T08:39:08+00:00\",\"description\":\"Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam (NASDAQ: ALNY), securing rights to co-develop and co-commercialize Alnylam\u2019s zilebesiran, a Phase II stage RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15881#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15881\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15881#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam (NASDAQ: ALNY), securing rights to co-develop and co-commercialize Alnylam\u2019s zilebesiran, a Phase II stage RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15881","og_locale":"en_US","og_type":"article","og_title":"Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15881","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-25T08:15:00+00:00","article_modified_time":"2024-11-30T08:39:08+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15881#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15881"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment","datePublished":"2023-07-25T08:15:00+00:00","dateModified":"2024-11-30T08:39:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15881"},"wordCount":269,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Alnylam Pharmaceutical","High blood pressure","NASDAQ: ALNY","RNAi \/ ASO","Roche","SWX: ROP"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15881#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15881","url":"https:\/\/flcube.com\/?p=15881","name":"Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-25T08:15:00+00:00","dateModified":"2024-11-30T08:39:08+00:00","description":"Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam (NASDAQ: ALNY), securing rights to co-develop and co-commercialize Alnylam\u2019s zilebesiran, a Phase II stage RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15881#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15881"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15881#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15881"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15881\/revisions"}],"predecessor-version":[{"id":15882,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15881\/revisions\/15882"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}